New IQVIA data show medicine prices grew just 1.5 percent in 2018
By Holly Campbell | January 29, 2019
Last year, the U.S. Food and Drug Administration approved a record of 59 novel new medicines. During this incredible era of innovation, medicine prices grew just 1.5 percent in 2018, after...
Read More
Health Affairs study misses the mark on medicine costs
By Holly Campbell | January 28, 2019
A recent study published in Health Affairs concludes that list price inflation for existing brand medicines is a key driver of rising medicine spending. However, by failing to account for the...
Read More
PhRMA comments to administration on Medicare Part D proposed rule
By Juliet Johnson | January 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the CMS proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and...
Read More
New research shows changes to the six protected classes would harm most vulnerable patients and are unnecessary
By Juliet Johnson | January 24, 2019
In Medicare Part D, the six protected classes policy protects vulnerable seniors and low-income beneficiaries with serious and complex health conditions, while also allowing Part D insurance plans...
Read More
Putting 2018 medicine approvals in context
By Andrew Powaleny | January 23, 2019
Last year, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). While...
Read More
Keep the Six Protected Classes, protected
By Juliet Johnson | January 22, 2019
Medicare Part D has been successfully providing seniors with comprehensive drug coverage for more than a decade, and one of the cornerstones of the program has been to ensure the sickest and most...
Read More
New government data show medicine price growth continues to decline
By Holly Campbell | January 18, 2019
Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.
Read More
New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions
By Holly Campbell | January 18, 2019
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not...
Read More
ICYMI: New study reinforces dangers of proposed IPI model
By Nicole Longo | January 15, 2019
Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in...
Read More
PhRMA comments to administration on International Pricing Index Model
By Nicole Longo | January 3, 2019
As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
